Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, by Type (Hereditary Transthyretin Amyloidosis (hATTR), and Wild Type Transthyretin Amyloidosis (wtATTR)), by Drug Type (Transthyretin Stabilizers, Nonsteroidal Anti-Inflammatory Drugs (NSAID

Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, by Type (Hereditary Transthyretin Amyloidosis (hATTR), and Wild Type Transthyretin Amyloidosis (wtATTR)), by Drug Type (Transthyretin Stabilizers, Nonsteroidal Anti-Inflammatory Drugs (NSAID), RNAi therapy, and Others), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies) and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2028

Transthyretin amyloid cardiomyopathy (ATTR-CM) is a common type of amyloidosis, which affects the heart, causing heart muscles to stiffen and eventually lead to heart failure. ATTR-CM often causes symptoms of heart failure, such as fatigue, shortness of breath and peripheral edema, and other symptoms related to buildup of amyloid fibrils in the body. There are two forms of transthyretin amyloid cardiomyopathy (ATTR-CM); hereditary transthyretin amyloidosis (hATTR) and wild type transthyretin amyloidosis (wtATTR). This disease is often diagnosed only after symptoms have become severe.
Market Dynamics
Rising incidence of transthyretin amyloid cardiomyopathy is expected to drive the transthyretin amyloid cardiomyopathy (ATTR-CM) treatment market growth. For instance, according to the National Center for Biotechnology Information (NCBI), an article published in December 2021, reports the study of the Japan Medical Data Vision (MDV), which was a hospital based database from January 2010 to September 2018 to estimate the number of currently diagnosed ATTR-CM patients. This study reports data of over 9 years of study which included 3255 patients (155.8 per million adult patients in the MDV database) to 3992 patients (191.1 per million) diagnoses of wild type transthyretin amyloidosis (wtATTR).
However, lack of awareness about transthyretin amyloid cardiomyopathy (ATTR-CM) is expected to hinder the market growth. For instance, according to an article published by Amyloidosis. Amyloidosis Foundation in 2016, awareness of transthyretin amyloid cardiomyopathy (ATTR-CM) is low among the general public as well as healthcare professionals and therefore, this condition often is unnoticed.
Key features of the study:
This report provides in-depth analysis of the global transthyretin amyloid cardiomyopathy (ATTR-CM) treatment market, and provides market size (US$ Mn) and compound annual growth rate (CAGR%) for the forecast period (2022-2028), considering 2021 as the base year
It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
This study also provides key insights about market drivers, restraints, opportunities, new drug launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
It profiles key players in the global transthyretin amyloid cardiomyopathy (ATTR-CM) treatment market based on the following parameters – company overview, financial performance, product portfolio, market presence, distribution strategies, key developments, strategies, and future plans
Key companies covered as a part of this study are Pfizer Inc., GlaxoSmithKline Plc., Eidos Therapeutics, Ionis Pharmaceuticals, Inc., Alnylam Pharmaceuticals, Prothena Corporation plc, Intellia Therapeutics, Inc., Corino Therapeutics, Inc. among others
Insights from this report would allow marketers and management authorities of companies to make informed decisions regarding future drug launches, drug class up-gradation, market expansion, and marketing tactics
The global transthyretin amyloid cardiomyopathy (ATTR-CM) treatment market report caters to various stakeholders in this industry including investors, suppliers, manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global transthyretin amyloid cardiomyopathy (ATTR-CM) treatment market.
Detailed Segmentation:
Global Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, By Type:
Hereditary Transthyretin Amyloidosis (hATTR)
Wild Type Transthyretin Amyloidosis (wtATTR)
Global Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, By Drug Type:
Transthyretin Stabilizers
Nonsteroidal anti-inflammatory drugs (NSAID)
RNAi therapy
Others
Global Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, By Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Global Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, By Region:
North America
By Type:
Hereditary Transthyretin Amyloidosis (hATTR)
Wild Type Transthyretin Amyloidosis (wtATTR)
By Drug Type:
Transthyretin Stabilizers
Nonsteroidal anti-inflammatory drugs (NSAID)
RNAi therapy
Others
By Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
By Country:
U.S.
Canada
Latin America
By Type:
Hereditary Transthyretin Amyloidosis (hATTR)
Wild Type Transthyretin Amyloidosis (wtATTR)
By Drug Type:
Transthyretin Stabilizers
Nonsteroidal anti-inflammatory drugs (NSAID)
RNAi therapy
Others
By Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
By Country:
Brazil
Mexico
Argentina
Rest of Latin America
Europe
By Type:
Hereditary Transthyretin Amyloidosis (hATTR)
Wild Type Transthyretin Amyloidosis (wtATTR)
By Drug Type:
Transthyretin Stabilizers
Nonsteroidal Anti-Inflammatory Drugs (NSAID)
RNAi therapy
Others
By Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
By Country:
Germany
U.K.
France
Italy
Spain
Russia
Rest of Europe
Asia Pacific
By Type:
Hereditary Transthyretin Amyloidosis (hATTR)
Wild Type Transthyretin Amyloidosis (wtATTR)
By Drug Type:
Transthyretin Stabilizers
Nonsteroidal Anti-Inflammatory Drugs (NSAID)
RNAi therapy
Others
By Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
By Country:
China
India
Japan
Australia
South Korea
ASEAN
Rest of Asia Pacific
Middle East
By Type:
Hereditary Transthyretin Amyloidosis (hATTR)
Wild Type Transthyretin Amyloidosis (wtATTR)
By Drug Type:
Transthyretin Stabilizers
Nonsteroidal Anti-Inflammatory Drugs (NSAID)
RNAi therapy
Others
By Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Others
By Country:
GCC
Israel
Rest of Middle East
Africa
By Type:
Hereditary Transthyretin Amyloidosis (hATTR)
Wild Type Transthyretin Amyloidosis (wtATTR)
By Drug Type:
Transthyretin Stabilizers
Nonsteroidal Anti-Inflammatory Drugs (NSAID)
RNAi therapy
Others
By Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
By Country/Region:
South Africa
Central Africa
North Africa
Company Profiles
Pfizer Inc.*
Company Overview
Product Portfolio
Financial Performance
Key Highlights
Market Strategies
GlaxoSmithKline Plc.
Eidos Therapeutics
Ionis Pharmaceuticals, Inc.
Alnylam Pharmaceuticals
Prothena Corporation plc
Intellia Therapeutics, Inc.
Corino Therapeutics, Inc.
“*” marked represents similar segmentation in other categories in the respective section.